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High level of susceptibility to human TRIM5α
conferred by HIV-2 capsid sequences
Junko S Takeuchi1,2, Benjamin Perche1,2, Julie Migraine1,2, Séverine Mercier-Delarue3, Diane Ponscarme4,
François Simon1,3, François Clavel1,2,3 and Béatrice Labrosse1,2*
Abstract
Background: HIV-2, which was transmitted to humans from a distant primate species (sooty mangabey), differs
remarkably from HIV-1 in its infectivity, transmissibility and pathogenicity. We have tested the possibility that a
greater susceptibility of HIV-2 capsid (CA) to the human restriction factor TRIM5α (hTRIM5α) could contribute to
these differences.
Results: We constructed recombinant clones expressing CA from a variety of HIV-2 viruses in the context of HIV-1
NL4-3-luciferase. CA sequences were amplified from the plasma of HIV-2 infected patients, including 8 subtype A
and 7 subtype B viruses. CA from 6 non-epidemic HIV-2 subtypes, 3 HIV-2 CRF01_AB recombinants and 4 SIVsmm
viruses were also tested. Susceptibility to hTRIM5α was measured by comparing single-cycle infectivity in human
target cells expressing hTRIM5α to that measured in cells in which hTRIM5α activity was inhibited by overexpression
of hTRIM5γ.
The insertion of HIV-2 CA sequences in the context of HIV-1 did not affect expression and maturation of the HIV-2
CA protein. The level of susceptibility hTRIM5α expressed by viruses carrying HIV-2 CA sequences was up to 9-fold
higher than that of HIV-1 NL4-3 and markedly higher than a panel of primary HIV-1 CA sequences. This phenotype
was found both for viruses carrying CA from primary HIV-2 sequences and viruses carrying CA from laboratory-
adapted HIV-2 clones. High hTRIM5α susceptibility was found in all HIV-2 subtypes. In this series of viruses,
susceptibility to hTRIM5α was not significantly affected by the presence of a proline at position 119 or by the
number of prolines at positions 119, 159 or 178 in HIV-2 CA. No significant correlation was found between HIV-2
viremia and sensitivity to hTRIM5α.
Conclusions: HIV-2 capsid sequences expressed high levels of susceptibility to hTRIM5α. This property, common to
all HIV-2 sequences tested, may contribute in part to the lower replication and pathogenicity of this virus in
humans.
Keywords: Primary HIV-2 strains, Human TRIM5α restriction factor, Capsid sequences
Background
Primate species have evolved under unrelenting selective
pressure by pathogenic lentiviruses. In response to
lentiviral infections, primates have selected a number of
restriction factors whose antiviral activity has subse-
quently become both species- and virus-specific. TRIM5α,
a restriction factor expressed by all primate species, exerts
its antiviral activity following entry through recognition of
the incoming lentiviral capsid, which leads to both prema-
ture destabilization of the capsid structure and abortive
reverse transcription, as well as induction of a cascade of
signal transduction events that is believed to promote
antiviral innate immune responses [1-5]. Human TRIM5α
(hTRIM5α), which appears to have been selected under
pressure by one or more ancient and presumably extinct
virus(es), only exerts limited restriction activity on the
lentiviruses that currently infect primate species [2,6,7]. In
particular, the antiviral activity of hTRIM5α on HIV-1 is
relatively low [8-12], with a few exceptions such as some
of the viral variants that have developed CTL resistance
mutations in CA epitopes presented by HLA-B*57 or -B*27
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[13]. Overall, the natural expression of TRIM5α in human
cells did not protect our species from pandemic-scale infec-
tion by HIV-1, following initial transmission of the virus to
humans from SIVcpz-infected chimpanzees.
The chimpanzee species from which HIV-1 originates
(Pan troglodytes troglodytes) is relatively closely related
to humans [14], suggesting that little adaptation may
have been needed on the part of HIV-1 to resist the anti-
viral activity of hTRIM5α and thereby propagate on an
epidemic scale in humans [15,16]. In contrast, HIV-2,
the other human lentivirus, is the result of transmission
of SIVsmm, a virus that naturally infects sooty manga-
beys (Cercopithecus torquatus atys) in Western Africa
[17-19]. The profile of HIV-2 infection in humans is
quite different from that observed with HIV-1. First, the
level of viral production, as measured by HIV-2 RNA in
plasma, is considerably lower than that of HIV-1 [20,21],
and also remarkably low compared to that of SIVsmm in
its natural host [22-24]. Second, the course of HIV-2
infection in humans is clearly longer and less pathogenic
than that of HIV-1, with a protracted asymptomatic period
followed, in some cases, by deterioration of CD4+ T
lymphocyte counts and immune deficiency [25-27]. Third,
HIV-2 transmission is less efficient than HIV-1 [28,29].
The geographic range of the HIV-2 epidemic, essentially
restricted to West Africa, has not significantly changed
since HIV-2 was first identified, while the range of HIV-1
infection has rapidly widened over this time period, yield-
ing the current pandemic stage. In several West African
countries where HIV-2 was predominant in the late 1980s,
HIV-1 has now become the dominant human lentiviral
infection [30,31]. Another strong indicator of the lower
transmissibility of HIV-2 is the markedly lower rate of
mother-to-child transmission in absence of preventive
therapy, compared to that of HIV-1 [32,33].
Several mechanisms have been invoked to explain these
differences: i) an intrinsic lower infectivity and pathoge-
nicity of HIV-2, an hypothesis that is not consistent with
the high level of SIVsmm replication in sooty mangabeys;
ii) a more efficient control of HIV-2 replication in humans
owing to a better induction or higher efficacy of human
adaptive or innate immune responses; iii) a higher sensi-
tivity of HIV-2 to human restriction factors, possibly due
to the fact that HIV-2 has been transmitted to humans
from a more distantly related simian species expressing
divergent restrictions factors. The latter hypothesis would
be consistent with the idea that HIV-2 has had a much
longer time to adapt to mangabey restriction factors than
to human restriction factors, if indeed the transmission of
this virus to our species is a relatively recent event. In this
regard, HIV-2 is divided into more than 8 subtypes
[34-37], which, unlike HIV-1 subtypes, but similar to the
HIV-1 M, N, O and P groups, generally correspond to
separate transmission events from non-human primate to
man. Subtypes A and B, which may have originated from
the same transmission event, are the dominant, so-called
epidemic subtypes, and are responsible for the vast
majority of HIV-2 infections. Other subtypes are mostly
sporadic, as they are represented by only a few or even a
single viral isolate.
Susceptibility of HIV-2 to human restriction factors
has not been extensively evaluated, and viral isolates that
had been adapted for replication in cultures of primary
or transformed human cells have often been used. In
particular, analyses on HIV-2 susceptibility to hTRIM5α
have been essentially restricted to studies on HIV-2
ROD [38,39], a highy laboratory-adapted HIV-2 isolate
[40], although a limited number of primary isolates have
also been studied using non-quantitative assays [41]. In
spite of this lack of direct information on the susceptibility
of primary HIV-2 strains to hTRIM5α, recent correlative
studies have suggested that inter-strain differences in
susceptibility to hTRIM5α or other CA-targeting restric-
tion factors, as reflected by specific polymorphisms in the
HIV-2 CA sequence, could contribute to differences in
the clinical progression of HIV-2 infection [42]. In this
study, we have examined the antiviral activity of hTRIM5α
on recombinant viruses expressing a wide panel of HIV-2
CA proteins directly amplified from the plasma of infected
patients. We conclude that HIV-2 capsids have higher
susceptibility to hTRIM5α than what is generally observed
with HIV-1. The level of susceptibility of HIV-2 CA to
hTRIM5α is comparable between different strains and
different subtypes of this virus, and is also comparable to
that of the SIVsmm CA. Thus, although susceptibility of
HIV-2 to hTRIM5α does not appear to play a determinant
role in the differences in pathogenic profiles observed
among HIV-2 infected patients, it may contribute to the
overall lower rate of replication and propagation of this
virus in humans.
Results
Maturation and biological properties of HIV-1 NL4-3-
derived chimeric viruses expressing HIV-2 CA sequences
To examine the susceptibility of primary HIV-2 to
hTRIM5α, we constructed chimeric clones expressing
plasma-derived HIV-2 CA coding sequences in the
context of an HIV-1 backbone. The backbone was
pNL4-3-ΔENV-LucR [43], which permits optimal virus
production and highly sensitive quantification of HIV-1
infectivity on a single-cycle basis. As shown on Figure 1,
HIV-2 or SIV CA coding sequences (aa 17 to 224) were
inserted between the HIV-1 MA/CA and CA/p2 clea-
vage site sequences, thereby preserving the HIV-1
identity of these sequences, and allowing optimal
proteolytic cleavage of the HIV-2 CA by the HIV-1 prote-
ase expressed by the pNL4-3-derived vector. The HIV-2
and SIV CA sequences were categorized as follows: i) CA
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from laboratory adapted HIV-2 strains GL-AN and
ROD10; ii) CA from primary plasma-derived HIV-2
sequences, including 8 subtype A and 7 subtype B viruses,
iii) CA from HIV-2 CRF01_ AB NMC (Nagoya Medical
Center) 307, NMC716 and NMC842 viruses, iv) synthetic
CA sequences from 6 non-epidemic HIV-2 (subtypes C
to H), 4 SIVsmm strains, and SIVmac239, and v) CA
from 9 primary HIV-1 belonging to subtypes B and
CRF02_AG.
CA maturation in the chimeric viruses was analyzed
by western blot after purification by ultracentrifugation
of virions over a 20% sucrose cushion, normalization for
RT content by ELISA and reaction with a mixture of
human sera from HIV-2 positive patients. As shown on
Figure 2A, chimeric virions contained high amounts of
fully mature p26 CA protein, together with small amounts
of higher molecular weight Gag cleavage intermediates.
The ratio of fully processed CA to cleavage intermediates
was comparable to that observed for pNL4-3 particles,
although the pattern of incompletely processed Gag
proteins was different in the two virion preparations. The
profile of incompletely cleaved Gag proteins was similar
among the different HIV-2 CA-expressing chimeric
virions studied.
To further validate that the mature capsids of these
chimeric viruses had biological properties expected from
HIV-2, we also examined their susceptibility to the
cyclophilin A (CypA) antagonist Debio-025. Indeed,
while most HIV-1 strains have been described as being
susceptible to CypA antagonists, the replication of HIV-
2 has been consistently reported to be unaffected by
these antagonists, a property that is related to specific
genetic traits of its CA protein [44-46]. As expected, and
in contrast with the HIV-1 control virus, no detectable
inhibition of viral infectivity by Debio-025 was observed
for the two chimeric viruses carrying HIV-2 CA se-
quences tested (Figure 2B). This observation indicates
that these viruses had acquired biological properties
consistent with that of expression of a functional HIV-2
CA protein, making them suitable for hTRIM5α suscep-
tibility testing.
Infectivity and susceptibility to hTRIM5α of viruses
expressing HIV-2 CA
Infectivity of recombinant viruses carrying HIV-2 and SIV
CA sequences was tested in a luciferase-based single-cycle
assay in U373-X4-hTRIM5γ cells, in which the antiviral
activity of hTRIM5α is offset by stable overexpression of
hTRIM5γ. Stocks of viruses were produced by transfection
of 293T cells and normalized for RT content by ELISA. To
ensure that no viral propagation would occur in the target
cell cultures, virus particles were pseudotyped with VSV-
G. The results of viral infectivity obtained using U373-X4-
hTRIM5α cells, which were pretreated with IFNα before
infection, are presented on Figure 3A. The viruses were
grouped according to the origin of their CA proteins:
laboratory-adapted HIV-2 strains (n=2), HIV-2 clinical
isolates from subtype A (n=8) or from subtype B (n=7),
CRF01_AB (n=3), synthetic sequences from HIV-2 viruses
from non-epidemic subtypes C to H (n=6), synthetic
sequences from SIVsmm (n=4) and from SIVmac239. The
results were compared to those obtained for NL4-3 and to
those from a panel of recombinant viruses expressing CA
from a panel of primary HIV-1 plasma sequences. This
panel included recombinant virus NRC10-5, a previously
described NL4-3 derived virus carrying the CA sequences
from a clinical isolate that expresses high susceptibility to
hTRIM5α [12,13]. For the HIV-2 CA recombinants,
NL4-3 SQNYPIVQNLQGQMVHQAISPRTLNAWVKVVEE----//-----MMTACQGVGGPGHKARVLAEA
GL-AN GRNFPVQQTGGGNYIHVPLSPRTLNAWVKLVED----//-----MLTACQGVGGPGQKARLMAEA
ROD10 GGNYPVQHVGGNYTHI-PLSPRTLNAWVKLVEE----//-----MLTACQGVGGPGQKARLMAEA
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Figure 1 Chimeric viruses carrying HIV-2 CA sequences. The HIV-1 pNL4-3-ΔENV-LucR vector, in which the SacII and XmaI restriction sites
were introduced, was used as background to express a variety of HIV-2 and SIV CA sequences. The aminoacid alignment of the extended capsid-
coding region of the HIV-1 NL4-3, and the HIV-2 strains GL-AN and ROD10 is shown. The HIV-1 Gag sequences recognized by the HIV-1 protease
are highlighted in grey, and the MA/CA and CA/p2 cleavage sites are indicated. The arrows underline the sequences of primers carrying the SacII
and XmaI restriction sites, which were used to clone the HIV-2 CA sequences. The aminoacids present into wild-type or chimeric pNL4-3-∆ENV-LucR
are in bold. MA, matrix; CA, capsid.
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infectivity values ranged from 1×104 to 8×106 relative light
units (RLU)/0.2 ng of RT (Figure 3A), but no virus group
displayed infectivity levels that differed significantly from
those of any of the other groups (p > 0.05). The mean
infectivity values of viruses carrying primary HIV-1 CA
and NL4-3 CA were 6×104 and 3×108 RLU/0.2 ng of RT,
respectively. Among the panel of our chimeric viruses,
one of the seven viruses carrying CA from a primary HIV-
2 subtype B and one of the four viruses carrying CA from
a SIVsmm strain could not be tested phenotypically for
their susceptibility to hTRIM5α since their infectivities
were less than 4×104 RLU/0.2 ng of RT (Figure 3A).
Susceptibility to hTRIM5α was expressed as the ratio
of viral infectivity measured in U373-X4-hTRIM5γ cells
to that measured in U373-X4-LacZ control cells. This
method has been shown by our laboratory to be fully
valid for hTRIM5α susceptibility testing of viruses carry-
ing primary HIV-1 Gag sequences [12,13]. Susceptibility
to hTRIM5α of viruses expressing HIV-2 CA is shown
on Figure 3B. Overall, susceptibility of most HIV-2 CA-
carrying viruses was greater than that measured for
HIV-1 NL4-3. Highest susceptibility values were found
with viruses expressing CA from laboratory-adapted
HIV-2 strains GL-AN and ROD10, respectively 6.4-fold
(p = 0.0086) and 8.9-fold (p = 0.0016) more susceptible
to hTRIM5α than NL4-3. The lowest susceptibility
values were measured in viruses CA from non-epidemic
HIV-2 subtypes (mean = 3.3). Susceptibility values for
this series of viruses were markedly heterogeneous,
ranging from 7.5-fold for CA from HIV-2 subtype F to
1.4-fold with CA from HIV-2 subtype G. Such hete-
rogeneity was not observed for viruses expressing
SIVsmm CA. As expected, hTRIM5α susceptibility
values obtained for viruses carrying primary HIV-1 CA
was low (mean = 2.0-fold), including 8 viruses for which
susceptibility values ranged 1.4- to 2.3-fold. Consistent
with previous observations, the susceptibility of NRC-10,
which expresses mutations conferring CTL resistance in
the HLA-B*27-targeted epitope KK10, was 4.7-fold.
Overall, susceptibility to hTRIM5α of primary HIV-1
CA-carrying viruses was significantly lower than
that measured for recombinant viruses carrying CA
from either HIV-2 subtype A (p = 0.001), HIV-2 sub-
type B (p = 0.008) or HIV-2 CRF01_ AB (p = 0.009),
respectively.
Absence of correlation between plasma viral loads and
hTRIM5α susceptibility
Quantification of plasma HIV-2 viral load (VL) was
performed by a method derived from that described by
Damond et al. [34], using a modified set of primers
targeting the 5'-long terminal repeat (5'-LTR) region with
a detection limit of 10 HIV-2 RNA copies/ml (Figure 4).
The quantification of viral load was performed on plasma
samples obtained from 8 HIV-2 subtype A-infected and 6
HIV-2 subtype B-infected patients for whom we were able
to reconstruct chimeric viruses and measure their sensi-
tivity to hTRIM5α. HIV-2 viral loads ranged from 1 to
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Figure 2 CA proteins expression and sensitivity of chimeric
viruses to Debio-025. (A) Western blotting. The particle-associated
proteins of HIV-1 NL4-3 (lane 2), HIV-1 expressing the capsid proteins
from the two laboratory-adapted HIV-2 GL-AN (lane 2) and ROD10
(lane 3), from two subtype A clinical isolates HIV-2 CA-A4 (lane 5), A8
(lane 6), and from a subtype B clinical isolate HIV-2 B1.2 (lane 7)
were analyzed. The viral supernatants of 293T transfected cells were
concentrated by ultracentrifugation, through 20% sucrose cushion,
resuspended and normalized by RT ELISA (0.3 ng) before western
blot analysis using a mixture of serum derived from HIV-2 subtype A
or B-infected patients. Lane 1: supernatant of untransfected 293T
cells. The location of the CA proteins is shown on the left. The
molecular mass marker (in kilodaltons) is indicated on the right.
Results are representative of three independent experiments. (B)
Effect of Debio-025 on viral infectivity. U373-X4 cells overexpressing
hTRIM5γ were pretreated for 20 h with 100 U/ml IFN-α, and infected
with equal amounts (0.2 ng RT) of the indicated VSV-G-pseudotyped
chimeric viruses in the presence of the indicated concentrations of
Debio-025. Forty hours after infection, medium was removed, the
cells were lysed, and luciferase activity was determined by
luminometry. The results, which are expressed relative to the
infectivity of that of untreated cultures, are the mean ± SEM for 3
experiments. Asterisks indicate the results of statistical analyses
comparing infectivity of chimeric virus to that of NL4-3, as
determined using the non-parametric Mann–Whitney test: **,
p = 0.0014; ***, p = 0.0001.
Takeuchi et al. Retrovirology 2013, 10:50 Page 4 of 11
http://www.retrovirology.com/content/10/1/50
5.15 Log10 RNA copies/ml, and were higher for HIV-2
subtype A-infected patients than for HIV-2 subtype B-
infected patients (mean values of 3.6 Log10 and 2.1 Log10
RNA copies/ml, respectively, p < 0.02). However, no
correlation was found between HIV-2 viral load and
susceptibility to hTRIM5α of the chimeric viruses carrying
the CA from these HIV-2 infected patients.
Impact of polymorphisms at positions 119, 159 and 178
of CA to hTRIM5α susceptibility
Song et al. [41] reported that HIV-2 propagation in
human cells overexpressing hTRIM5α is less efficient for
viruses carrying a proline at position 119 of CA protein,
as compared to that of viruses expressing a glutamine or
an alanine at this position. More recently, studies by
Onyango et al., evaluating HIV-2-infected patients from
Guinea Bissau, found that the concommittent presence
of a proline at CA positions 119, 159 and 178 is more
frequent in subjects with low VL while non-proline
aminoacids at these three sites are more frequent in sub-
jects with high VL [42]. The authors suggested that this
relationship could be explained by differences in suscep-
tibility to hTRIM5α.
To explore the potential impact of these variations on
the susceptibility to hTRIM5α, we grouped our HIV-1
chimeric viruses according to whether the residues at
CA positions 119, 159 and 178 were a proline (P) or
non-proline (N) amino acid. For these studies, the panel
of HIV-1 chimeric viruses studied was increased by
including of variants harboring CA sequences derived
from minority populations present in the plasma from
some of the infected patients. As shown on Figure 5A,
the mean hTRIM5α susceptibility ranged from 4.4 (NPP
viruses) to 7.8 (NPN viruses). Considerable overlap bet-
ween the different groups was observed, however, and
these differences were not statistically significant. In
addition, no correlation was observed between the
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Figure 3 Measurement of viral infectivity and susceptibility to
hTRIM5α. The U373-X4-hTRIM5γ and U373-X4-LacZ target cells were
pretreated for 20 h with 100 U/ml IFN-α before their infection with
0.2 ng RT of chimeric viruses. The viruses were grouped according
to the origin of their CA proteins: laboratory-adapted HIV-2 strains
(n=2), HIV-2 clinical isolates from subtype A (n=8) or from subtype B
(n=7), CRF01_AB (n=3), synthetic sequences from HIV-2 viruses from
non-epidemic subtypes C to H (n=6), synthetic sequences from
SIVsmm (n=4) and from SIVmac239, primary HIV-1 CA sequences
from patient plasma (n=9). Forty hours after luciferase activity was
determined by luminometry. (A) Infectivity values of chimeric viruses
measured in the U373-X4 target cells in which hTRIM5α activity had
been inhibited by overexpression of hTRIM5γ, which are expressed
as RLU/0.2 ng of RT. (B) Susceptibility values of chimeric viruses to
hTRIM5α were expressed as a ratio [(RLU for hTRIM5γ cells)/(RLU for
LacZ cells)], and normalized to that obtained for NL4-3. The results
shown are the mean ± SEM for 3 independent experiments.
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number of proline residues present at these three posi-
tions and hTRIM5α susceptibility.
We also analyzed the impact on hTRIM5α susceptibil-
ity of amino acid substitutions involving one or more of
these proline residues. Mutagenesis was performed on
the recombinant virus carrying CA from the GL-AN
strain, which, like its parental strain GH123 [47],
harbored proline residues at CA positions 119, 159 and
178. Modifying individually these proline residues (P119A,
P159S, P178A) did not significantly change viral suscepti-
bility to hTRIM5α, although the mutation P178A induced
a 1.3-fold increase compared with that of CA-GL-AN
(Figure 5B). Similarly, the double mutant P159S-P178A
and the triple mutant P119A-P159S-P178A had compa-
rable hTRIM5α susceptibilities (mean values of 7.0 and
6.4, respectively) that were not significantly different from
that of the CA-GL-AN virus (mean value of 6.4).
Discussion
The results presented here show that recombinant HIV-1
viruses carrying the CA protein from a panel of labora-
tory-adapted or primary HIV-2 strains express comparable
levels of susceptibility to human hTRIM5α, which we
found significantly increased compared to that of HIV-1.
These recombinant viruses were found to produce normal
amounts of fully proteolytically processed CA protein, the
likely result of inserting the HIV-2 CA between cleavage
site sequences that were spared in the cloning process and
that are specific for cleavage by the HIV-1 protease
expressed by the NL4-3 backbone. It is noteworthy that
the resulting recombinant viruses were less infectious than
the parental NL4-3 virus. This feature did not appear to
be attributable to a CA proteolytic processing defect, and
may be the consequence of some undefined structural
effect. We provide strong evidence, however, that these
viruses produced a capsid structure that is biologically
relevant to that of full length HIV-2. Of note, no corre-
lation was found between susceptibility to hTRIM5α and
infectivity. Furthermore, the chimeric viruses displayed
strong resistance to CypA antagonist Debio-025, a pheno-
type that is expected from viruses expressing a functional
HIV-2 CA protein.
Unlike earlier studies on HIV-2 susceptibility to
hTRIM5α, which mostly used partially quantitative propa-
gative assays, our study was based a highly sensitive and
reproducible single-cycle assay whose results have been
shown to be fully consistent with those of earlier studies
evaluating HIV-1. Human TRIM5α susceptibility was
evaluated by quantifying single-cycle infectivity in U373
cells expressing IFN-enhanced levels of hTRIM5α and
comparing it with that measured in cells in which the
antiviral activity of hTRIM5α has been stably obliterated
by overexpression of hTRIM5α, a truncated, inactive,
trans-dominant isoform of hTRIM5α lacking a PRYSPRY
domain. In previous work, it was established that this
system was better suited for measuring hTRIM5α antiviral
activity than partial disruption of hTRIM5α expression by
a miRNA-based approach. To enhance their infectivity,
virions were pseudotyped by the VSV-G envelope glyco-
protein, which, although it directs virus entry through a
route that differs from that of virions naturally expressing
HIV-1 Env, does not affect their sensitivity to hTRIM5α.
Using this system, we observed that almost all of the
viruses expressing HIV-2 capsid from the panel tested
here were significantly more susceptible to hTRIM5α than
HIV-1. Little difference was found comparing viruses
carrying CA from laboratory-adapted HIV-2 strains to
viruses expressing CA from primary, plasma-derived HIV-2
sequences. Moreover, no significant difference was seen
comparing viruses with HIV-2 CA derived from the two
main epidemic subtypes (subtypes A and B), viruses with
CA sequences from sporadic, non-epidemic subtypes or
from a novel recombinant A/B CRF_01 subtype. Similar
levels of susceptibility were also measured for viruses with
CA from three different representatives of SIVsmm. Over-
all, these findings suggest that hTRIM5α did not consti-
tute a strong barrier for transmission of SIVsmm to
humans. If that were the case, one would have expected to
see different levels of HIV-2 CA evolution and adaptation
to hTRIM5α leading to differences in susceptibility
Figure 4 Plasma viral loads and hTRIM5α susceptibility.
Quantification of plasma HIV-2 viral load (Log10 RNA copies/ml) was
performed on plasma samples obtained from 8 HIV-2 subtype
A-infected and 6 HIV-2 subtype B-infected patients for whom we
measured their sensitivity to hTRIM5α. Linear regression curve
(continuous line) and 95% CI (dotted line) are presented. The
correlation coefficient and p value were calculated by
Spearman test.
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according to the virus strain, with strongest adaptation
in laboratory-adapted strains and lowest adaptation in
sporadically transmitted non-A non-B subtypes and in
SIVsmm.
Our study provides further evidence that susceptibility
to hTRIM5α does not constitute a decisive factor for
adaptation and replication of HIV-2 in humans. First, we
failed to observe any significant correlation between
susceptibility to hTRIM5α and HIV-2 plasma viral load,
which was only measured in patients from the HIV-2
cohort infected with HIV-2 subtypes A or B. HIV-2
plasma RNA was measured using a quantitative PCR
assay targeting well-conserved HIV-2 LTR sequences
and yielding viral load levels that were clearly higher than
those measured with the PCR assay targeting gag used in
our prior studies. With this assay, most if not all tested
patients displayed detectable viremia ranging from ≥ 10 to
141,254 copies/ml, with a median of 704 copies/ml.
Second, our findings do not support the idea that the
number and pattern of proline residues at positions 119,
159 and 178 of the HIV-2 CA can have a strong impact
on sensitivity to hTRIM5α, and that certain of these
patterns are associated with higher levels of HIV-2 replica-
tion and HIV-2 disease progression in vivo [42]. Among
the panel of HIV-2 primary CA sequences tested in our
study, no significant correlation appeared between the
number and pattern of proline residues at these positions
and either hTRIM5α sensitivity or viral load. Consistent
with these findings, modifying the profile of these proline
residues in a virus expressing CA from laboratory-adapted
HIV-2 GL-AN did not have striking effects on its suscepti-
bility to hTRIM5α. Thus, although changes in these resi-
dues may influence sensitivity to hTRIM5α in some
isolates, this effect appears to be dependent on the CA
context in which the modifications are introduced. Thus,
the profile of proline residues cannot be used as a reliable
surrogate marker for identifying viruses that are sensitive
or resistant to hTRIM5α.
In conclusion, our findings reveal that hTRIM5α did not
constitute a significant barrier to transmission of HIV-2 in
humans and that no apparent adaptation of HIV-2 CA
towards lower hTRIM5α susceptibility appears to have oc-
curred either in vivo or during the in vitro propagation of
Figure 5 Impact of the CA residues 119, 159, and 178 on
hTRIM5α susceptibility. (A) hTRIM5α susceptibility of HIV-1
chimeric viruses that are stratified by the presence of proline (P) or
no proline residue (N) at each of the CA positions 119, 159 and 178.
For example, PPP = proline residues at positions 119, 159 and 178,
NNN = no proline at the three positions. (B) hTRIM5α susceptibility
values of HIV-1 chimeric virus carrying GL-AN capsid sequence
(CA-GL-AN) and of its corresponding mutants CA-GL-AN P119A,
CA-GL-AN P159S, CA-GL-AN P178A, CA-GL-AN P159S-P178A, and CA-
GL-AN P119A- P159S-P178A were compared. The results shown are
the mean ± SEM for 3 independent experiments.
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HIV-2 in human cells. Most HIV-2 strains, however, dis-
play a significantly higher level of susceptibility to
hTRIM5α compared to that of HIV-1. This lack of adapta-
tion, in spite of higher susceptibility, may be explained by
a high genetic barrier to adaptation in the context of the
HIV-2/SIVsmm CA sequence. Such evolution may require
the introduction of complex sets of genetic changes, and
the sequential introduction of these mutations may be
prevented if the virus encounters important troughs in
intrinsic fitness and/or resistance to hTRIM5α during the
acquisition of the necessary mutations. Thus, it remains
possible that the higher susceptibility of HIV-2 to
hTRIM5α participates to some extent to the lower patho-
genicity and replication efficiency of this virus in humans.
However, the lack of correlation between susceptibility to
hTRIM5α and HIV-2 plasma viral load strongly suggests
that other factors, independent from this restriction factor,
may be altered during in vivo progression of HIV-2
disease.
Conclusion
In conclusion, our studies indicate that the susceptibility
to hTRIM5α of HIV-1 chimeric viruses carrying a wide
panel of HIV-2 CA proteins was higher than what is
generally observed with HIV-1. This level hTRIM5α
susceptibility is comparable between different strains
and different subtypes of HIV-2, and is also comparable
to that of the SIVsmm CA. Furthermore, no significant
correlation was found between HIV-2 viremia and sensi-
tivity to hTRIM5α. Overall, these findings suggest that
hTRIM5α did not constitute a decisive factor for adapta-
tion and replication of HIV-2 in humans.
Methods
Reagents
Alpha interferon (IFNα) (Sigma-Aldrich) was dissolved in
deionized water (final concentration, 2 × 105 U/ml), and
stored in aliquots at −80°C. Debio-025 (kindly provided by
Debiopharma, Lausanne, Switzerland) was dissolved in di-
methyl sulfoxide (DMSO) at a final concentration of 10
mM, and stored in aliquots at −80°C.
Cell culture
293T and U373-X4 cell lines were cultured in Dulbeccos
modified Eagles medium supplemented with 10% fetal
calf serum, 100 U/ml penicillin G and 100 μg/ml strep-
tomycin. The two U373-X4 cell lines used as target cells,
have previously been described [12]: (i) U373-X4 cells
over-expressing human TRIM5γ (hTRIM5α cells), which
has a dominant-negative effect against endogenous
human TRIM5α; (ii) U373-X4 cells over-expressing LacZ
(LacZ cells), which were used as a control. Human
TRIM5γ cells and LacZ cells were maintained in the
presence of 10 μg/ml puromycin, 100 μg/ml hygromcin
B, and 8 μg/ml blasticidin.
Construction of HIV-1 viruses expressing HIV-2 CA or SIV
CA proteins
To generate recombinant viruses expressing CA se-
quences from HIV-2 and SIV viruses, we used the HIV-1
pNL4-3-ΔENV-LucR vector as background, which con-
tains Renilla luciferase reporter gene in place of the HIV-1
nef locus and carries a large deletion in env [43]. To facili-
tate the construction of CA chimeric proviruses, SacII and
XmaI restriction sites were introduced at positions 49 and
670 of the CA domain of pNL4-3-ΔENV-LucR, respec-
tively, using the QuickChange site-directed mutageneis kit
(Stratagene), thereby creating pNL4-3-ΔENV-LucR-SX
(Figure 1). The HIV-2 and SIV capsid sequences tested in
this study were derived from different origins.
CA sequences from primary HIV-2 subtypes A and B
We used frozen plasma samples from 15 infected patients
of the French ANRS HIV-2 cohort to generate recombi-
nant viruses expressing CA sequences derived from either
primary HIV-2 subtype A (CA-A1 to CA-A8) or subtype
B (CA-B1 to CA-B7). To concentrate viral particles,
plasma samples were ultracentrifugated (TLA 100.4 rotor;
OptimaTM TLX ultracentrifuge; Beckman Instruments)
at 164,000 × g for 30 min at 4°C in 3.2 ml polycarbonate
tubes (Beckman), and RNA purification was performed
using the QIAamp Viral RNA Mini kit (Qiagen). Extracted
RNAs were directly used for reverse transcriptase-PCR
(RT-PCR) amplification or stored at −80°C until use. The
RT-PCR reaction was performed with the SuperScript III
One-Step RT-PCR (Invitrogen) using the following pri-
mers: HIV-2-CA-F1 (5-CCGCTGAGTCCCCGAACTCT
AAAT) and HIV-2-CA-R1 (5-CCTCCTTTAAGGCTTC
TGCCATTA). For three RNA samples, the CA domain
(CA-A2, CA-B3, and CA-B6) was amplified with the
following primer set: HIV-2-CA-F2 (5-GAAGTTGCGR
GGCTTCTTTCCC) and HIV-2-CA-R2 (5-GTAGACCA
ACAGCACCACCTAG). The nested PCR reaction was
performed using the Accuprime Pfx Supermix (Invitrogen)
and the primers: CA-SacII-F (5-AGCCCGCGGACCCTA
AATGCCTGGGTAAA) and CA-XmaI-R (5-TTTCTGCC
CGGGGCCACCTACCCCCTG).
CA sequences from primary HIV-2 CRF01_AB
The plasmids coding the gag region of the HIV-2
CRF_01 AB originating from three different patients [48]
[NMC (Nagoya Medical Center) 307, NMC716 and
NMC842; kindly provided by Dr. Ibe were used to amp-
lify the CA domain using the primers CA-SacII-F and
CA-XmaI-R.
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CA sequences from laboratory-adapted HIV-2 ROD10 and
GL-AN
The proviral molecular clones pGL-AN and pROD10
were kindly provided by Dr. Nguyen and Dr. Adachi
[47,49] and by Dr. Peden [50], respectively. The corre-
sponding CA sequences were amplified with the primers
CA-SacII-F and CA-XmaI-R. Five recombinant viruses
carrying GL-AN capsid sequence with one or more
mutations introduced by site-directed mutagenesis were
constructed: P119A (CA-GL-AN P119A), P159S (CA-GL-
AN P159S), P178A (CA-GL-AN P178A), P159S+P178A
(CA-GL-AN P159S-P178A), and P119A+P159S+P178A
(CA-GL-AN P119A-P159S-P178A).
Each PCR product was verified by agarose gel electro-
phoresis and column purified (Qiagen) prior to sequen-
cing, and was subcloned into the pCR2.1 vector (TOPO
TA cloning Kit, Invitrogen). Six to eight independent
clones were sequenced for each bulk PCR product, and
in most cases only clones possessing the sequence that
matched the majority sequence were cloned into the
HIV-1 pNL4-3-ΔENV-LucR-SX vector.
Synthetic CA sequences from non-epidemic HIV-2 and SIV
CA sequences derived from six non epidemic HIV-2 sub-
types: subtype C (Genbank accession number L33077
[36]), D (L33083 [36]), E (L33087 [36]), F (U75441 [51]),
G (AF208027 [52]), and H (AY530889 [35]), four SIVsmm
(L09213 [53], AB553975 [54], U72748 [55], and X14307
[56]), and SIVmac239 (M33262 [57]), were commercially
synthesized (GenScript). Since, the complete CA sequen-
ces of HIV-2 subtypes C, D, E, and F were not available
from the Los Alamos database their C-terminal regions
(~ 50 aminoacids) were complemented by a SIVsmm
sequence (X14307 [56]).
Quantification of plasma viral load
The HIV-2 viral load measurements were performed at
Hôpital Saint-Louis using the real-time quantitative PCR
method for measuring the HIV-2 RNA load as previously
described [34], with the exception that a new set of
primers overlapping the 5'-long terminal repeat (5'-LTR)
region allowing to distinguish between HIV-2 subtypes A
and B. Six of these patients were clinically considered as
aviremic with viral loads below 200 RNA copies/ml.
Production of chimeric viruses
The pNL4-3-ΔENV-LucR-SX vector or the correspon-
ding chimeric proviruses (1 μg) and a VSV-G expression
plasmid (phCMV-G, 0.1 μg) were cotransfected into
5×104 293T cells seeded into 6 well plates using jetPEI
reagent (PolyPlus Transfection). Virus-containing cul-
ture supernatants were harvested 40 h after transfection,
clarified by centrifugation to remove cell debris, assayed
for their reverse transcriptase (RT) content using the
HS-Lenti RT activity kit (Cavidi AB), and used directly
for western blot analysis and infectivity assays.
Western blotting
The VSV-G-pseudotyped HIV-1 NL4-3-derived particles
were harvested 40 h post-transfection, purified and
concentrated by centrifugation through a 20% sucrose
cushion at 110,000 × g for 90 min using a TLA 100.4 rotor
and an Optima TLX Ultracentrifuge (Beckman Coulter)
and then resuspended in 50 μl Laemmli sample buffer
(Bio-Rad). Particle-associated proteins corresponding to
0.3 ng of RT were separated by gel electrophoresis into a
12% SDS-PAGE gel, transferred to a PVDF membrane
(Whatman), and blocked in Odyssey western blot blocker
for 3 h at room temperature. To analyze the Gag process-
ing pattern an to detect HIV-2 CA proteins, the mem-
branes were probed with a mixture of sera derived from
HIV-2 subtype A- and B-infected patients at a 1:2,000
dilution for 2 h at room temperature, washed, incubated
with a HRP-conjugated goat anti-human IgG - H&L
(ab6858, Abcam) at a 1:20,000 dilution for 1 h at room
temperature, and detected using a ECL Advance western
blotting detection Kit (RPN2135, GE healthcare).
Measurement of viral infectivity
Each viral infectivity was measured by determining Renilla
luciferase activity in target cells 40 h after infection, as
previously described [12]. Briefly, the U373-X4-hTRIM5γ
and/or the U373-X4-LacZ target cells (1 × 104 cells) were
initially plated in black-walled, clear bottom 96-well plates,
cultured in the presence of 100 U/ml IFNα for 20 h to
increase the expression of TRIM5α, and infected with 2 ng
RT/ml of virus supernatant. After 40 hours, the supernatant
of adherent cells was completely removed and 50 μl of 1X
lysis buffer (Renilla Luciferase kit, Promega) were added to
each well. Plates were maintained at room temperature for
30 min, after which wells were sequentially injected with
100 μl of luciferase substrate (Promega), and three seconds
later, light emission (relative light units, RLU) was mea-
sured over a two sec interval using a luminometer
(Varioskan Flash, Thermo scientific). Each sample was eva-
luated in triplicate and three independent experiments were
performed. Results were expressed as mean for three
experiments.
Effect of Debio-025 on viral infectivity
The U373-X4-hTRIM5γ target cells were pretreated for
20 h with 100 U/ml IFNα and with 0.05 μM or 1 μM
Debio-025 for 15 min before viral infection (0.2 ng of RT).
Infectivity values are expressed relative to those of cells
not pretreated with Debio-025 and infected with the
same virus.
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Measurement of hTRIM5α susceptibility
The U373-X4-hTRIM5γ and the U373-X4-LacZ target
cells were pretreated for 20 h with 100 U/ml IFNα
before infection with 0.2 ng RT/ml of virus supernatant.
The results were expressed as a ratio [(RLU for hTRIM5γ
cells)/(RLU for LacZ cells)], and normalized to results
obtained for NL4-3.
Statistical analysis
All results are expressed as mean ± standard error of the
mean (SEM). Comparisons between two groups were
performed using the MannWhitney test; comparisons
between multiple groups within a single series of experi-
ments were performed using the Kruskal-Wallis test;
post-test comparisons, performed only if p < 0.05, were
performed using Dunns multiple comparison test. In all
cases, GraphPad Prism 5 software was used.
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